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ABSTRACT
Aim and Objective: The aim of the study was to evaluate the role of Vitamin E supplementation in Type II diabetes mellitus (DM), to determines 
whether people with Type II DM treated with hypoglycemic agents alone, with or without Vitamin E, to determines the drug interaction in such 
treatment regimen, and to evaluates the Safety of the regimen.
Methods: Type II DM patients with or without complications were included in this study along with serum glycated hemoglobin (HbA1c) concentration 
between 7.5% and 9.5%. They are divided into test group (which received hypoglycemic agent along with Vitamin E 4000 IU) and control group. Body 
mass index (BMI) status, fasting blood sugar (FBS), and post-prandial blood sugar (PPBS) were noted once in a month, HbA1c percentage, total 
cholesterol level (TC), and serum Vitamin E level were estimated and noted for every 3 months at total 9 months of this study. Patients with other 
comorbid conditions were prominent in this study.
Results: It is perceptible with the analysis of obtained data that FBS, PPBS, HbA1c percentage, TC level, and BMI status of the patients were declined 
gradually in test group (patients with Vitamin E supplementation along with their hypoglycemic agents). Thus, antioxidant therapy is highly propitious 
whereby delaying the onset of complications in patients with DM. This development would be highly helpful for diabetic patients.
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INTRODUCTION
Diabetic may be a cluster of metabolic diseases characterized by 
symptoms that are hyperbolic blood glucose level ensuring from 
defects in endocrine secretion, endocrine action, or both [1]. Toxic gas 
free radicals are involved within the pathological process of diabetes, 
and its small and macrovascular complications [1]. An imbalance which 
ends from an inflated production and/or the reduced scavenging of 
those free radicals ends up in a metabolic state of aerophilous stress 
that consequently ends up in tissue injury. Motorcar glycosylation 
reactions alterations within the sorbitol pathway and hyperglycemia 
are planned as a number of the mechanisms that square measure 
accountable for this inflated aerophilous stress [2,3]. The injury that 
is finished to the building block by the reactive gas species (oxidative 
damage) is unbroken under control by a network of inhibitor defense 
and repair systems that square measure synthesized inside the 
physique [4,5]. In addition, antioxidants square measure obtained 
from the diet. One in all the most effective characterized of those is 
Vitamin E, a vitamin that helps in preventing injury to the lipids by 
the gas free radicals. When highly-reactive species attack the lipids 
inside the membranes or the lipoproteins, they depart the chain 
reaction of supermolecule per chemical reaction [6]. Vitamin E halts 
this chain reaction, for example, it acts as a sequence breaking matter 
of supermolecule per chemical reaction. The chronic symptoms of the 
polygenic disease are related to long harm, dysfunction, and failure of 
various organs, together with eyes, kidney, nerves, heart, and blood 
vessels, Vitamin E has inhibitor activity [7,8]. It’s going to even have 
antiatherogenic, antithrombotic, medicinal drug, neuroprotective, 
antiviral, and immunomodulatory. Vitamin E may be a collective 
term used to describe eight separate forms, the best-known form 
being alpha-tocopherol [9]. Vitamin E is a fat-soluble vitamin and 
is an important antioxidant. It acts to safeguard cells against the 
results of free radicles, that square measure the probably measuring 
by-products of the body’s metabolism [11-13]. Antioxidant such 
as Vitamin E facilitates defend against the damaging effects of free 
radicles, which can contribute to the event of chronic disease such 
as cancer, complications in diabetes mellitus (DM). It additionally 
protects alternative fat-soluble vitamins (A and cluster vitamins) 
from destruction y element. Low levels of Vitamin E are joined to the 
hyperbolic incidence of long-time complication in DM [14-16].
METHODS
Type II DM patients with or without complications were included in this 
study along with serum glycated hemoglobin (HbA1c) concentration 
above 7.5%. They were divided into a test group (which received 
hypoglycemic agents along with Vitamin E) and the control group. Body 
mass index (BMI) status, fasting blood sugar (FBS), post-prandial blood 
sugar (PPBS), HbA1c percentage, total cholesterol (TC) level, and serum 
Vitamin E level were estimated and noted for every 3 months at total 
9 months of this study. Patients with other comorbid conditions were 
prominent in this study.
Study design
A prospective study has been carried out with patient’s case sheets.
Evaluation test
Serum glucose and HbA1c are monitored 1 week before treatment 
initiation, on the day of initiation, 1st and 12th weeks.
Statistical analysis
Efficacy is analyzed on the basis of Chi-square test with 95% safety is 
assessed using student t-test with 95%.
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RESULTS
Table 1 indicates the gender distribution where male patients were higher 
in number than female patients. Table 2 shows age distribution, number 
of patients participating from different age groups. Fig. 1 illustrates the 
BMI of the patients of different age groups. Fig. 2 illustrates the comorbid 
conditions of patients participating in this study; hypertension is 
commonly seen in almost all the patients. Table 3 indicates the base line, 
average values before treatment. In Fig. 3, the graph indicates the BMI 
status of the test (Group B) and control (Group A) groups, where the 
BMI status of the test group was decreased gradually. Table 4 indicates 
the FBS, Table 5 with PPBS, Table 6 shows the Hba1c levels of test and 
control groups, where there was a significant decline in the test groups 
of all three different blood sugar investigation. Table 7 indicates the TC 
Table 1: Gender distribution
S. No Gender Number of patients
1 Male 70
2 Female 30
Table 2: Age distribution










BMI: Body mass index
Table 4: Baseline characteristics
S. No Characteristics Group A Group B p value
1 Male 36 34 0.9716
2 Age (years) 57.61±3.8 51.62±1.96 0.0827
3 BMI 24.6±1.8 23.9±2.1 0.0721
4 FBS 161.6±13.4 168±14.6 0.0517
5 PPBS 239.6±18.82 237.6±16.41 0.0978
6 HbA1c 8.3±0.6 8.7±0.4 0.0589
7 Sr. Vitamin E levels 3.9±0.8 4.06±0.7 0.0578
8 LDL 137.6±3.2 134.8±7.1 0.0921
9 TC 214.6±16.8 227.4±13.2 0.0582
10 HDL 47.6±3.8 44.9±2.8 0.0716
All values are Mean±SEM. BMI: Body mass index, FBS: Fasting blood sugar, 
PPBS: Post-prandial blood sugar, HbA1c: Glycated hemoglobin, 
LDL: Low-density lipoprotein, TC: Total cholesterol, HDL: High-density 
lipoprotein, SEM: Standard error of the mean
Table 5: BMI




BMI: Body mass index
Fig. 1: Body mass index
level of patients participating in the test and control groups, where there 
is a significant decrease in the test group compared to the control group. 
Table 8 indicates the serum Vitamin E level of both the groups where 
the patients belonging test group were highly benefited with gradually 
increase of serum Vitamin E level in their body. Fig. 8 shows that there 
was no significant Adverse Drug Reaction in this study. It is perceptible 
with the analysis of obtained data that the FBS, PPBS, HbA1c percentage, 
TC level, and BMI status of the patients were declined gradually in the 
test group (patients with Vitamin E supplementation along with their 
hypoglycemic agents). Thus, the antioxidant therapy is highly propitious 
whereby delaying the onset of complications in patients with DM. This 
development would be highly helpful for diabetic patients.
DISCUSSION
At the initial stage, the history of the patients was collected. General 
physical examinations and systemic examinations were carried out. 
The routine blood parameters such as FBS, PPBS, HbA1c and serum 
Vitamin E level were estimated. A routine urine examination was done. 
The patients were followed up once a month, and HbA1c percentage 
and serum Vitamin E level were noted for every 3 months at total 
9 months of this study. The history regarding the complications was 
Table 6: Fasting blood sugar
S. No Groups Group A Group B p value
1 Pre-treatment 161.6±13.4 168.3±14.6 0.0517
2 Post-treatment 149.7±12.6 139.6±10.2 0.0497
3 p value 0.0521 0.0317
All values are mean±SEM. SEM: Standard error of the mean
Table 7: Post‑prandial blood sugar
S. No Groups Group A Group B p value
1 Pre-treatment 296±3.64 290±3.15 0.0921
2 Post-treatment 288±3.21 264±3.16 0.0495
3 p value 0.0317 0.0392
All values are mean±SEM. SEM: Standard error of the mean
Table 8: HbA1c
S. No Groups Group A Group B p value
1 Pre-treatment 8.3±0.6 8.7±0.4 0.0589
2 Post-treatment 7.9±0.7 6.9±0.32 0.0417*
3 p value 0.0591 0.0321*
All values are mean±SEM. SEM: Standard error of the mean
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taken. The routine investigations were done. Fundoscopic examinations 
were done. The electrocardiography was recorded. Patient counseling 
regarding medication and diet were given. In Tables 6-8 and Figs 4-7, 
FBS, PPBS, and Hba1c levels were gradually decreased in test group 
where the patients in the test group consumed Vitamin E capsule 
along with their regular hypoglycemic medication, the decline was 
statistically significant which was similar to the result of Jain et al., 
in Table 9, there was a significant decline in the TC level in patients 
of test Group, which was statistically significant which was similar to 
the result of Kuznetsov et al. and Devaraj and Jialal [10], concluded 
that the Type II DM patients who were supplemented with tocopherol 
had a gradual decrease in lipid peroxidation and the free radical 
production by the circulating monocytes. Table 10 shows a gradual 
increase in Vitamin E level in patients who have been prescribed 
with Vitamin E supplementation. Fig. 9 shows the ADR report where 
there is no significance difference in both the groups. Hence, it also 
Fig. 2: Comorbid conditions
Fig. 3: Body mass index
Fig. 4: Fasting blood sugar
Fig. 5: Post‑prandial blood sugar
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decreased the markers of inflammation, which included the C-reactive 
protein, interleukin (IL)-1 and IL-6 [17-19]. Fewer studies prove that 
tocopherols improve the retinal blood flow in patients encountered 
with diabetic retinopathy complication and thus slowing down the 
onset of much other complication in Type II DM patients [20,21].
CONCLUSION
Vitamin E therapy in DM significantly reduces HbA1c and FBS, post-
prandial in subjects with low and poor glycemic control. Thus, a long-
term antioxidant therapy - Vitamin E is beneficial, as it slows down the 
onset and slowing down the progression of complications.
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